Long-Acting Drug Delivery Strategies for Precision Nanomedicine

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 1993

Special Issue Editor


E-Mail Website
Guest Editor
1. Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025 Barcelona, Spain
2. Josep Carreras Leukaemia Research Institute, 08025 Barcelona, Spain
3. CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Majadahonda, Spain
4. Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
Interests: nanomedicine; cancer therapy; protein materials; targeting; drug delivery systems; self-assembling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the development of precision nanomedicines, many efforts are being made in order to improve the pharmacokinetics of administered drugs, as this is an effective way to enhance their therapeutic outcome. In this sense, current therapies are still mainly based on the intravenous administration of small molecules, which show short biological half-lives and, in consequence, require multiple doses. This administration pattern, far from being effective, generates large fluctuations in blood drug concentration and significantly increases the risk of potential side effects, strongly limiting their use in clinic. Therefore, there is an urgent need to develop innovative, long-acting drug delivery systems that allow the sustained-release of the administered drug over a long period of time, from several days to weeks. This approach not only significantly enhances the pharmacokinetics of the drug by maintaining its constant level in the blood during the treatment, but also improves patients quality of life and increases adherence to the therapy.

This Special Issue entitled “Long-Acting Drug Delivery Strategies for Precision Nanomedicine” expects to collect current research progresses in the development of therapeutic drug delivery systems, that allow the sustained release of different types of drugs into de blood stream for improved pharmacokinetics and therapeutic efficiency. Therefore, this Special Issue invites all researchers working on this field to contribute with their original research articles and reviews.

Dr. Ugutz Unzueta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • drug delivery system
  • sustained release
  • pharmacokinetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1702 KiB  
Article
Efficient Delivery of Antimicrobial Peptides in an Innovative, Slow-Release Pharmacological Formulation
by Naroa Serna, Hèctor López-Laguna, Patricia Aceituno, Mauricio Rojas-Peña, Eloi Parladé, Eric Voltà-Durán, Carlos Martínez-Torró, Julieta M. Sánchez, Angela Di Somma, Jose Vicente Carratalá, Andrea L. Livieri, Neus Ferrer-Miralles, Esther Vázquez, Ugutz Unzueta, Nerea Roher and Antonio Villaverde
Pharmaceutics 2023, 15(11), 2632; https://doi.org/10.3390/pharmaceutics15112632 - 16 Nov 2023
Cited by 5 | Viewed by 1658
Abstract
Both nanostructure and multivalency enhance the biological activities of antimicrobial peptides (AMPs), whose mechanism of action is cooperative. In addition, the efficacy of a particular AMP should benefit from a steady concentration at the local place of action and, therefore, from a slow [...] Read more.
Both nanostructure and multivalency enhance the biological activities of antimicrobial peptides (AMPs), whose mechanism of action is cooperative. In addition, the efficacy of a particular AMP should benefit from a steady concentration at the local place of action and, therefore, from a slow release after a dynamic repository. In the context of emerging multi-resistant bacterial infections and the urgent need for novel and effective antimicrobial drugs, we tested these concepts through the engineering of four AMPs into supramolecular complexes as pharmacological entities. For that purpose, GWH1, T22, Pt5, and PaD, produced as GFP or human nidogen-based His-tagged fusion proteins, were engineered as self-assembling oligomeric nanoparticles ranging from 10 to 70 nm and further packaged into nanoparticle-leaking submicron granules. Since these materials slowly release functional nanoparticles during their time-sustained unpacking, they are suitable for use as drug depots in vivo. In this context, a particular AMP version (GWH1-NIDO-H6) was selected for in vivo validation in a zebrafish model of a complex bacterial infection. The GWH1-NIDO-H6-secreting protein granules are protective in zebrafish against infection by the multi-resistant bacterium Stenotrophomonas maltophilia, proving the potential of innovative formulations based on nanostructured and slowly released recombinant AMPs in the fight against bacterial infections. Full article
(This article belongs to the Special Issue Long-Acting Drug Delivery Strategies for Precision Nanomedicine)
Show Figures

Figure 1

Back to TopTop